Anteris Technologies (ASX: AVR) stock up 9.6% as PARADIGM trial reaches first US patient enrolments

Anteris Technologies (ASX: AVR) shares advanced 9.62 per cent to A$9.80 on Friday, lifting market capitalisation to A$153 million and taking the twelve-month return to 43 per cent. The dual-listed Australian-American structural heart company is developing the DurAVR Transcatheter Heart Valve, a balloon-expandable aortic valve replacement that is positioned to compete directly with Edwards Lifesciences and Medtronic in the global transcatheter aortic valve replacement market. The PARADIGM pivotal trial enrolled its first US patients in May 2026 following CMS Medicare reimbursement coverage in April, and Medtronic completed a US$90 million strategic investment in January as part of a US$320 million combined capital raise. With the global registration-enabling trial now active across multiple geographies, the next inflection is the trial’s recruitment pace and the eventual one-year primary endpoint readout.

What is DurAVR and why is it differentiated from existing TAVR valves?

The DurAVR Transcatheter Heart Valve System is a balloon-expandable aortic valve replacement comprised of the DurAVR valve, ADAPT tissue, and the ComASUR balloon-expandable Delivery System. ADAPT tissue is FDA-cleared and has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide, which provides a long-tenure safety record for the underlying tissue material. The valve design is positioned to deliver improved hemodynamics and durability compared with current commercial TAVR options. For patients with severe aortic stenosis, TAVR is the standard of care for those at high or intermediate surgical risk, and is increasingly used in lower-risk patients as long-term data supports broader application. The DurAVR clinical hypothesis is that improved hemodynamics translate into better long-term outcomes including reduced cardiovascular hospitalisation and improved survival, which is the basis of the PARADIGM trial design.

How is the PARADIGM trial structured and what makes it a pivotal study?

The PARADIGM Trial is a prospective, randomised controlled multicenter, international study in which subjects will be randomised to receive either the DurAVR THV or TAVR using commercially available and approved THVs in an All Comers Randomized Cohort. The trial will enrol approximately 1,000 patients with 1:1 randomisation, assessing non-inferiority on a primary composite endpoint of all-cause mortality, all stroke, and cardiovascular hospitalisation at one year post procedure. Subjects with a failed surgical bioprosthesis in need of a valve-in-valve TAVR will be enrolled in a separate parallel registry. The PARADIGM trial is designed to provide the primary clinical evidence on which the FDA could base a decision for Premarket Approval, required for US commercialisation, with CE Mark approval expected to progress in parallel. Recruitment commenced in Europe in October 2025, US sites activated in May 2026, and the trial is supported by early clinical experience from over 130 patients treated with the DurAVR THV.

Why is Medtronic’s US$90 million strategic investment material beyond the capital?

In January 2026, Anteris completed a US$90 million strategic investment from Medtronic, the world’s largest medical technology company, alongside an underwritten public offering of common stock for combined gross proceeds of US$320 million. Medtronic and Anteris are aligned around the belief that reshaping the TAVR market requires advancing clinical science and valve design while maintaining rigorous standards for durability, hemodynamics, and long-term patient outcomes. The strategic significance extends beyond the capital. Medtronic is one of two dominant incumbents in TAVR alongside Edwards Lifesciences, and its investment in a competitor valve programme is unusual. The investment validates the DurAVR programme at a strategic level, signals potential future commercial alignment, and provides Anteris with relationships that accelerate trial site activation. The CEO Wayne Paterson described the investment as a major strategic validation from a key innovator.

How does the CMS Medicare coverage determination accelerate US patient recruitment?

In April 2026, Anteris secured US Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare and Medicaid Services national coverage policy. Eligible procedures performed at participating US study sites are covered under the Transcatheter Aortic Valve Replacement National Coverage Determination 20.32. The reimbursement coverage matters because it removes the financial friction that otherwise slows trial enrolment at US sites. Hospitals and physicians require reimbursement clarity before activating new trial protocols, and the CMS coverage establishes that pathway. The first US patients were enrolled and treated during May 2026, demonstrating the practical effect of the reimbursement determination. Recruitment is expected to expand into additional countries to further accelerate enrolment, with the goal of completing the 1,000-patient All Comers Randomized Cohort within the trial’s planned timeline.

How does the macro TAVR market context support Anteris’s commercial thesis?

The global TAVR market is estimated at approximately US$6 billion annually and growing at high single-digit to low double-digit rates as the procedure expands into lower-risk patient populations. Edwards Lifesciences and Medtronic dominate the market with their Sapien and CoreValve Evolut platforms respectively, and a third entrant with differentiated hemodynamic performance could capture meaningful share if the clinical data supports the positioning. The market dynamics also favour the surgical-to-transcatheter migration that has defined the past decade, with TAVR penetration continuing to increase across developed markets. The risk is that Edwards and Medtronic continue to iterate their existing platforms, potentially closing the differentiation gap that DurAVR is targeting. The PARADIGM non-inferiority design is structured to deliver a regulatory pathway even without superiority on the primary composite endpoint, with hemodynamic superiority as a supporting clinical narrative.

What does the Q1 2026 financial position reveal about runway and dilution risk?

Anteris reported a US$28.7 million cash outflow in Q1 2026 reflecting the investment phase of the PARADIGM trial execution. The US$320 million January capital raise materially strengthened the balance sheet and should fund execution through the bulk of the trial enrolment period. The PARADIGM trial is supported by early clinical experience from over 130 patients treated with the DurAVR THV across the EMBARK Study, the US Early Feasibility Study, and other prior cohorts. ISO 13485 certification for DurAVR THV production has been achieved, and the company has completed the first double DurAVR implant in a patient receiving valve-in-valve replacement in both the mitral and aortic valve positions. Manufacturing scale-up is advancing alongside the clinical programme. For retail investors, the question is whether the US$320 million plus the strategic Medtronic relationship is sufficient to reach commercialisation without further material dilution.

What execution risks should retail investors weigh in the DurAVR story?

Three risks dominate. First, trial outcome. The PARADIGM primary endpoint at one year post-procedure is the gating event for FDA Premarket Approval, and any underperformance against the non-inferiority threshold materially compresses the commercial thesis. Second, competitive iteration. Edwards Lifesciences and Medtronic both continue to advance their TAVR platforms, and the clinical differentiation that DurAVR is targeting could narrow by the time PARADIGM completes. Third, capital structure. While the January raise was substantial, completing a global pivotal trial and preparing for commercial launch is capital-intensive, and additional financing may be required closer to commercialisation. The dual ASX and NASDAQ listing provides flexibility on capital sources, but each raise carries dilution. Retail discussions reflect awareness of the binary nature of pivotal trial readouts and the multi-year timeline to commercialisation.

What are the key takeaways for retail investors watching Anteris Technologies?

• The PARADIGM pivotal trial enrolled its first US patients in May 2026 following CMS Medicare reimbursement coverage in April, and is now active across Europe and the United States.
• The Medtronic US$90 million strategic investment in January 2026 validates the DurAVR programme at a strategic level and is unusual coming from a dominant TAVR incumbent.
• The US$320 million combined January capital raise provides runway through trial execution, with Q1 2026 cash outflow of US$28.7 million indicating the investment intensity.
• DurAVR’s clinical hypothesis of improved hemodynamics is structured to deliver regulatory pathway under non-inferiority while building a commercial narrative on hemodynamic superiority.
• Execution risks centre on the one-year PARADIGM primary endpoint, competitive iteration from Edwards Lifesciences and Medtronic, and capital structure through to commercialisation.